U.S. Tech Hardware Stock News

NYSE:VSCO
NYSE:VSCOSpecialty Retail

Assessing Victoria’s Secret (VSCO) Valuation After Fresh Inflation Jitters Hit Consumer Stocks

The latest stronger than expected US Producer Price Index reading has pushed inflation worries back into focus, pressuring apparel names such as Victoria's Secret (VSCO) as investors reassess risks to discretionary consumer spending and earnings resilience. See our latest analysis for Victoria's Secret. That inflation scare comes after a powerful rebound, with a 30 day share price return of 15.02% and a 90 day share price return of 49.39%, while the 1 year total shareholder return of 161.14%...
NasdaqGS:LKFN
NasdaqGS:LKFNBanks

How Strong Q4 Earnings, Dividend Hike, and Insider Buying Will Impact Lakeland Financial (LKFN) Investors

Lakeland Financial’s recent update included fourth-quarter 2025 earnings that topped consensus estimates, a 4% increase to its quarterly cash dividend paid in February 2026, and director Welch M Scott’s purchase of 10,000 common shares in late February. These events, alongside mixed analyst opinions and contrasting insider transactions, highlight a tension between external research views and internal confidence at the company. We’ll now examine how the stronger-than-expected quarterly...
NasdaqGS:IQ
NasdaqGS:IQEntertainment

Reassessing iQIYI (IQ) Valuation After Sustained Share Price Weakness

Setting the scene for iQIYI (NasdaqGS:IQ) iQIYI (NasdaqGS:IQ) has been under pressure recently, with the share price weaker over the month and past 3 months. This has prompted investors to reassess how its current valuation lines up with recent financial results. See our latest analysis for iQIYI. The latest 1 day share price return of a 6.43% decline extends a weaker trend, with the 30 day share price return down 23.08% and the 1 year total shareholder return down 20.79%. This suggests...
NYSE:CVS
NYSE:CVSHealthcare

A Look At CVS Health (CVS) Valuation After Tennessee Bill 2040 And Insurance Business Retrenchment

CVS Health (CVS) is in the spotlight after Tennessee Senate Bill 2040 advanced, threatening to force the closure of all company pharmacies in the state. CVS also plans to scale back Medicare Advantage and exit Obamacare exchanges. See our latest analysis for CVS Health. At a share price of US$79.90, CVS has seen a 7.22% 1 month share price return and a modest 2.94% 3 month share price return. Its 1 year total shareholder return of 27.81% points to stronger longer term momentum as investors...
NYSE:WTTR
NYSE:WTTREnergy Services

Assessing Select Water Solutions (WTTR) Valuation After Secondary Equity Offering And Growth Outlook

Select Water Solutions (WTTR) is back in focus after a US$175 million secondary equity offering and a new shelf registration, moves the company says will fund water infrastructure projects, potential acquisitions, and possible debt repayment. See our latest analysis for Select Water Solutions. The equity raise and new shelf filing come after a period of strong momentum, with a 90 day share price return of 32.33% and a 5 year total shareholder return of 104.63%, even though the share price...
NasdaqGS:ZBRA
NasdaqGS:ZBRAElectronic

Did New AI Lumber Scanning Win Just Shift Zebra Technologies' (ZBRA) Industrial Automation Narrative?

In February 2026, Zebra Technologies announced that EBI Electric is using its AltiZ 3D sensors and Aurora Imaging software to power Inspector T, an AI-enriched lumber scanning solution that boosts measurement precision and helps mills cut waste while optimizing yield from every plank. The Inspector T system’s ability to detect subtle wood defects and recover up to 5% more usable lumber, with potential annual cost savings near US$750,000 per mill, highlights how Zebra’s machine-vision and AI...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

Assessing Ardelyx (ARDX) Valuation After Strong 2025 Results And 2026 Growth Guidance

Earnings and Guidance Put Ardelyx in Focus Ardelyx (ARDX) has drawn fresh attention after reporting full year 2025 results and issuing 2026 revenue guidance that highlights expected growth in IBSRELA and XPHOZAH sales. For investors watching the stock, the combination of higher 2025 revenue, a wider net loss, and specific product level guidance for 2026 sets the stage for reassessing the company’s risk and reward profile. See our latest analysis for Ardelyx. At a share price of US$6.55,...
NYSE:VLO
NYSE:VLOOil and Gas

How Investors May Respond To Valero Energy (VLO) Refinery Idling, Low‑Carbon Pivot And Biofuel Rule Shifts

In recent months, Valero Energy reported quarterly earnings that surpassed consensus expectations, advanced plans to idle its Benicia refinery by April 2026, and outlined increased investments in low‑carbon projects, while facing new US biofuel blending proposals that could raise compliance costs for large refiners. These developments highlight how Valero is reshaping its refining footprint and fuel mix at the same time that shifting regulations directly affect its operating economics. We’ll...
NYSE:MCK
NYSE:MCKHealthcare

Assessing McKesson (MCK) Valuation After Q3 Earnings Beat And Upgraded Earnings Outlook

Why McKesson’s latest earnings report matters for shareholders McKesson (MCK) shares were in focus after fiscal Q3 2026 results came in ahead of analyst expectations, with management lifting its full-year non-GAAP earnings growth outlook to a range of 17 to 19%, pointing to momentum across oncology and biopharma services. See our latest analysis for McKesson. At a share price of US$987.37, McKesson has seen strong recent momentum, with a 30 day share price return of 18.79% and a 1 year total...
NYSE:CRS
NYSE:CRSAerospace & Defense

Carpenter Technology CEO Succession Plan Meets Strong Share Price Momentum

Carpenter Technology (NYSE:CRS) has outlined a CEO succession plan with Brian Malloy scheduled to become Chief Executive Officer on July 1, 2026. Current CEO Tony Thene is expected to transition to the role of Executive Chairman as part of the planned leadership change. Malloy brings operational experience at Carpenter Technology and prior industry leadership that may influence future company priorities. Carpenter Technology enters this planned leadership transition with its shares at...
NYSE:DBD
NYSE:DBDTech

A Look At Diebold Nixdorf (DBD) Valuation After Recent Share Price Momentum

What the recent move in Diebold Nixdorf means for investors With no single headline event driving trading, Diebold Nixdorf (DBD) has drawn attention after its shares closed at US$80.00, alongside positive month and past 3 months total returns. For investors watching shorter term momentum, the stock shows a 1 day return of about a 3.7% decline, a 7 day gain near 0.6%, roughly 15.9% over the past month, and about 21.9% across the past 3 months. See our latest analysis for Diebold Nixdorf. That...
NasdaqGS:FELE
NasdaqGS:FELEMachinery

Franklin Electric (FELE) Valuation Check After Mixed 2025 Results And New 2026 Sales Guidance

Franklin Electric (FELE) reported its fourth quarter and full year 2025 results, along with 2026 sales guidance, giving investors fresh detail on recent profitability trends and the company’s forward revenue expectations. See our latest analysis for Franklin Electric. The latest earnings update and 2026 sales guidance arrive after a period where short term momentum has been picking up. The 7 day share price return is 4.51% and the 90 day share price return is 4.55%, while the 1 year total...
NYSE:PRLB
NYSE:PRLBMachinery

How Proto Labs' (PRLB) New ProDesk AI Platform Has Changed Its Investment Story

In February 2026, Proto Labs launched ProDesk, an all-in-one online platform offering AI-powered real-time quoting, design-for-manufacturability analysis, and collaborative tools across injection molding, CNC machining, and 3D printing to streamline prototyping and production workflows. A key insight is that ProDesk centralizes AI-driven DFM feedback, part management, and engineering support in a single, shareable dashboard for product development and procurement teams, aligning with the...
NYSE:COR
NYSE:CORHealthcare

Is Cencora’s New Veterinary Stem Cell Cold Chain Altering The Investment Case For COR?

Gallant, an animal health biotechnology company, recently announced a fulfillment agreement with MWI Animal Health, part of Cencora, to build the first ultra-low temperature cold chain for veterinary medicine and support nationwide distribution of a potential first FDA-approved off-the-shelf veterinary stem cell therapy, pending conditional FDA approval. This partnership highlights Cencora’s growing role in specialized logistics for complex biologics, expanding its capabilities in animal...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Assessing Gilead Sciences (GILD) Valuation After Strong Recent Shareholder Returns

What Gilead Sciences stock is offering investors right now Gilead Sciences (GILD) is back on investors’ radar as its shares trade around $148.95, with recent returns over the past month and past 3 months prompting closer attention to its valuation and fundamentals. See our latest analysis for Gilead Sciences. At a share price of $148.95, Gilead Sciences has a 90 day share price return of 20.21% and a 1 year total shareholder return of 32.01%. The 3 year and 5 year total shareholder returns of...
NYSE:ASGN
NYSE:ASGNIT

Is ASGN (ASGN) Quietly Rewiring Its Global Strategy Around AI-Led Offshore Delivery?

ASGN Incorporated recently filed a US$9.58 million shelf registration for 225,000 common shares tied to its ESOP and announced new Commercial Segment leaders, including Ashish Jandial as President, Commercial North America, and Sangita Singh as President, India and International, following Sean Casey’s retirement and transition to Executive Advisor. These leadership changes, paired with the planned Everforth rebrand and Quinnox acquisition, signal a coordinated push to scale AI-led digital...
NasdaqGM:HLMN
NasdaqGM:HLMNMachinery

Is Hillman Solutions’ (HLMN) Pro Push and Buybacks Quietly Redefining Its Growth Playbook?

In February 2026, Hillman Solutions Corp. reported fourth-quarter 2025 sales of US$365.14 million and full-year sales of US$1.55 billion, alongside a move from a quarterly net loss to net income, issued 2026 net sales guidance of US$1.60 billion to US$1.70 billion, outlined an active bolt-on M&A pipeline, and completed a US$12.41 million share repurchase program covering 1,369,568 shares. Beyond the headline figures, management’s emphasis on Pro-focused expansion, a “healthy” acquisition...
NYSE:CRC
NYSE:CRCOil and Gas

Assessing California Resources (CRC) Valuation After Mixed Earnings And Growing Low Carbon Momentum

California Resources (CRC) just posted fourth quarter and full year 2025 results, with revenue higher than a year ago but net income and earnings per share lower. This keeps investor focus on earnings quality and capital allocation. See our latest analysis for California Resources. The latest move to a US$58.84 share price comes after a 24.1% 90 day share price return and a 53.4% 1 year total shareholder return. This suggests momentum has been building as investors weigh earnings, methane...
NasdaqGS:BKR
NasdaqGS:BKREnergy Services

Assessing Baker Hughes (BKR) Valuation After A Strong Multi Month Share Price Run

Baker Hughes: recent share move puts fundamentals in focus Baker Hughes (BKR) has drawn fresh attention after a strong recent run, with the stock showing double digit returns over the month and past 3 months. This performance is prompting investors to reassess its current valuation and business mix. See our latest analysis for Baker Hughes. The recent momentum is not just a one month story. Baker Hughes has a 30 day share price return of 16.45%, a year to date share price return of 38.44%,...
NYSE:CB
NYSE:CBInsurance

Strong Q4 Earnings, Dividend Hike and Deals Might Change The Case For Investing In Chubb (CB)

In late February 2026, Chubb Limited reported strong fourth-quarter 2025 results, highlighted by a 24.7% rise in net income, record investment income, and the Board’s plan to recommend a quarterly dividend increase to US$1.02 per share, marking what would be the company’s 33rd consecutive annual dividend raise. Alongside these earnings and dividend moves, Chubb refreshed key leadership positions in its actuarial and third-party administration businesses and expanded its Healthy Paws...
NYSE:AVY
NYSE:AVYPackaging

Will Stricter Shareholder Disclosures Reshape Avery Dennison's (AVY) Governance Narrative and Investor Engagement?

On February 26, 2026, Avery Dennison’s board approved amended and restated bylaws that, among other changes, require shareholders to disclose any material interest in business they propose for stockholder meetings. The bylaw overhaul, which also tightens disclosure around shareholder proposals and director nominations, could meaningfully affect how actively engaged investors interact with the company’s board. We’ll now examine how this added shareholder disclosure requirement may influence...
NYSE:IBP
NYSE:IBPConsumer Durables

Record Profitability, Bigger Dividends, New Buyback Might Change The Case For Investing In IBP (IBP)

In late February 2026, Installed Building Products reported fourth-quarter and full-year 2025 results showing slightly lower quarterly sales of US$747.5 million but higher net income of US$76.6 million, alongside dividend increases, a new US$500 million share repurchase authorization, and plans to pursue further acquisitions supported by recently issued senior notes and stronger liquidity. An interesting angle is how IBP combined record profitability and a 19% adjusted EBITDA margin with...
NYSE:PLNT
NYSE:PLNTHospitality

A Look At Planet Fitness (PLNT) Valuation After 2025 Beat And Cautious 2026 Outlook

Planet Fitness (PLNT) is back in focus after its fourth quarter and full year 2025 results, where higher revenue and net income met a cautious 2026 outlook and triggered a sharp shift in investor sentiment. See our latest analysis for Planet Fitness. That cautious 2026 outlook and the legal overhang have weighed on sentiment, with a 1 day share price return decline of 1.93% and a 90 day share price return decline of 24.48%. Meanwhile, the 3 year total shareholder return is roughly flat,...
NasdaqGS:UTHR
NasdaqGS:UTHRBiotechs

Why United Therapeutics (UTHR) Is Up 6.2% After Phase 3 Ralinepag Success And Strong Earnings

United Therapeutics recently reported that its long-term pivotal phase 3 ADVANCE OUTCOMES trial in pulmonary arterial hypertension met its primary endpoint, with ralinepag cutting the risk of clinical worsening events versus placebo and showing consistent benefits across secondary measures and patient subgroups, while maintaining a safety profile in line with existing prostacyclin therapies. This successful trial, coupled with the company’s latest quarterly results showing higher...